VSTM - Verastem, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.9000
+0.1400 (+1.60%)
As of 10:45AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close8.7600
Open8.7700
Bid8.8700 x 4000
Ask8.8800 x 1800
Day's Range8.7381 - 9.0300
52 Week Range2.7700 - 10.3500
Volume639,960
Avg. Volume2,506,789
Market Cap654.971M
Beta3.73
PE Ratio (TTM)N/A
EPS (TTM)-1.6840
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?
    Zacksyesterday

    Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?

    Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

  • Analysts Are Bullish on Verastem in September
    Market Realist7 days ago

    Analysts Are Bullish on Verastem in September

    On September 11, Verastem (VSTM) stock closed at $9.17, which is ~13% below its 52-week high of $10.35 on September 4. On September 6, Verastem announced that the company completed dosing the first patient with duvelisib and venetoclax combination therapy for the multicenter phase 1/2 trial at the Dana-Farber Cancer Center. Verastem is evaluating the safety and efficacy of duvelisib and venetoclax combination therapy for the treatment of individuals with relapsed or refractory chronic lymphoblastic leukemia or small lymphocytic lymphoma.

  • ACCESSWIRE12 days ago

    This Cancer Stock is up Over 3900%

    HENDERSON, NV / ACCESSWIRE / September 7, 2018 / A fascinating biotech firm we discovered PPCB (Propanc Biopharma, Inc.) erupted for over 7000% in the last ten trading session going from a low of $0.0039 ...

  • Business Wire13 days ago

    Verastem Oncology Announces Investigator Sponsored Study on Duvelisib in Combination with Venetoclax

    Verastem, Inc. (VSTM), operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  • Business Wire15 days ago

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to eleven new employees to purchase an aggregate of 202,230 shares of Verastem Oncology's common stock. The options were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $9.87 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on September 4, 2018.

  • Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
    SmarterAnalyst20 days ago

    Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks

    Hedge fund manager Mitchell J. Blutt of the $1.5 billion Consonance Capital fund has made some intriguing portfolio shifts in the last quarter, including boosting his position in biopharma firm Catalyst Pharmaceuticals (NASDAQ:CPRX) and initiating stakes in drug makers Verastem (NASDAQ:VSTM) and Sesen Bio (NYSE:SESN). Blutt is seizing the opportunity with Catalyst, dialing up his hedge fund firm’s stake in the company to the tune of a 22% boost up.

  • Benzinga20 days ago

    The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 29) Acceleron Pharma Inc (NASDAQ: XLRN ) Abbott Laboratories (NYSE: ...

  • Business Wire21 days ago

    Verastem Oncology Appoints Robert E. Gagnon as Chief Financial Officer

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the appointment of Robert E. Gagnon, an experienced financial executive, as Chief Financial Officer, effective August 28, 2018. A stock option to purchase 350,000 shares of Verastem Oncology’s common stock will vest as to 25% of the shares on the first anniversary of the date of hire and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the date of hire, provided that Mr. Gagnon continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

  • Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?
    Zacks29 days ago

    Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?

    Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

  • Here's Why Verastem Jumped Higher Today
    Motley Foollast month

    Here's Why Verastem Jumped Higher Today

    Hint: It has nothing to do with yesterday's earnings release.

  • ACCESSWIRElast month

    Pot Stocks & Biotech Stocks to Watch in 2018 & Beyond

    CORAL GABLES, FL / ACCESSWIRE / August 9, 2018 / Healthcare and biotechnology indexes are in the green this morning along with major markets pushing higher. The iShares Biotechnology Index (IBB) has risen an impressive 8.9% this year and has begun turning toward its 52-week high. GT Biopharma (GTBP) is a small cap biotech company with a vast pipeline of treatments.

  • Associated Presslast month

    Verastem: 2Q Earnings Snapshot

    On a per-share basis, the Needham, Massachusetts-based company said it had a loss of 30 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wirelast month

    Verastem Oncology Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to fifty-seven new employees to purchase an aggregate of 1,031,500 shares of Verastem Oncology’s common stock. The options were granted as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $7.74 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on August 1, 2018.

  • Business Wirelast month

    Verastem Oncology Reports Second Quarter 2018 Financial Results

    Verastem, Inc. , focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today reported financial results for the quarter ended June 30, 2018 and provided an overview of certain corporate developments.

  • ACCESSWIRE2 months ago

    Undiscovered Biotech Firm that Could Make Investors Early Very Happy

    HENDERSON, NV / ACCESSWIRE / July 30, 2018 / Biotech companies that are advancing their research are the type of company that, smart investors are actively looking for. One small cap biotech company that we have discovered BRTX (BioRestorative Therapies, Inc.). As BRTX prepares for it's Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar of most investors, which presents a great opportunity to investors that are currently in the know on BRTX.

  • ACCESSWIRE2 months ago

    Upcoming Catalysts Could Send This Unknown Stock Up 300% or More

    Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks

    Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...

  • Business Wire2 months ago

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to nine new employees to purchase an aggregate of 201,500 shares of Verastem Oncology’s common stock. The options were granted as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $6.95 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on July 2, 2018.

  • Business Wire3 months ago

    Verastem Oncology to Participate in the Oppenheimer Boston Oncology Insight Summit

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will participate in the Oppenheimer Boston Oncology Insight Summit on July 10-11, 2018, in Boston, Massachusetts. Members of Verastem Oncology’s executive team will participate in the event. Verastem, Inc. (VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients.

  • Business Wire3 months ago

    Verastem Oncology to Join Russell 3000® Index

    Verastem, Inc. (VSTM), the Company or Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will join the broad-market Russell 3000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective upon the US market open on Monday, June 25, 2018. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • ACCESSWIRE3 months ago

    Biotech's Making Great Progress

    HENDERSON, NV / ACCESSWIRE / June 22, 2018 / This is set to be the fifth consecutive quarter in which at least ten biotech companies have made it to market on an U.S. exchanges and have raised at least ...

  • ACCESSWIRE3 months ago

    Verastem Upcoming FDA Review, Big Steps Forward in the Oncology Space

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Verastem, Inc. (VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. The company recently announced the acceptance of its duvelisib New Drug Application by the U.S. Food and Drug Administration, with a Priority Review date later this year. The company recently made one oral and three poster presentations at the 23rd Congress of the European Hematology Association.

  • Analysts’ Recommendations for Verastem
    Market Realist3 months ago

    Analysts’ Recommendations for Verastem

    This month, Verastem (VSTM) and Yakult Honsha entered into an agreement where Yakult Honsha received the rights to develop and commercialize Verastem’s duvelisib for the treatment, prevention, and diagnosis of all oncology indications in Japan.

  • Why Verastem Stock Rose 31% on June 18
    Market Realist3 months ago

    Why Verastem Stock Rose 31% on June 18

    On June 18, Verastem (VSTM) stock rose ~31.4% from $6.53 on June 15 to close at $8.58, which represents ~319% growth from its 52-week low of $2.05 on June 19, 2017. The stock also hit its 52-week high of $8.75 on June 18. On June 15, Verastem stock rose ~17.0% to $6.53 from its previous close of $5.58 on June 14.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 18) Aptose Biosciences Inc (NASDAQ: APTO ) Arrowhead Pharmaceuticals ...